RedHill Biopharma Ltd.
) announced that the first patient has been dosed in the phase
III ERADICATE Hp study. This study evaluates the safety and
efficacy of RHB-105 as a first-line treatment for confirmed
Helicobacter pylori (H. pylori) bacterial infection.
The randomized, double-blind, placebo-controlled, phase III
study is expected to enrol 90 subjects. These patients will be
randomized in a 2:1 ratio to receive either RHB-105 or placebo
for a period of 14 days.
The primary endpoint of the study is the eradication of H.
pylori infection in a span of 28 to 56 days after completion of
treatment. RedHill Biopharma expects data from this study by the
third quarter of 2014.
H. pylori is a major cause of chronic gastritis, peptic ulcer
disease and gastric cancer; and mucosa associated lymphoid tissue
(MALT) lymphoma. As per the company, H. pylori affects two-thirds
of the world's population.
RedHill Biopharma has another interesting candidate in
RHB-104. In Nov 2013, the company commenced a double-blind,
placebo-controlled, phase III MAP U.S. study on RHB-104 for the
treatment of Crohn's disease. Apart from Crohn's disease, RedHill
Biopharma is also evaluating the candidate for the treatment of
multiple sclerosis (phase IIa proof of concept trial is going on)
and rheumatoid arthritis (plans for a phase IIa proof of concept
trial), and systemic lupus erythematosus.
RedHill Biopharma carries a Zacks Rank #2 (Buy). Some
better-ranked stocks include
Questcor Pharmaceuticals Inc.
Jazz Pharmaceuticals plc
). Each stock carries a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.